MV Credit supports Ephios Luxembourg's acquisition offer for SYNLAB AG, a leading European clinical laboratory and diagnostic services provider.

Information on the Target

SYNLAB AG is recognized as one of Europe’s foremost providers of clinical laboratory and medical diagnostic services. The company specializes in delivering a wide range of laboratory analyses and diagnostics to healthcare providers, ensuring high standards of quality and reliability. As a leader in its field, SYNLAB operates across various countries, enhancing its market presence and service capabilities.

With a strong commitment to innovation and technology, SYNLAB continuously invests in advanced diagnostic tools and methods. This approach not only enhances patient care but also supports healthcare providers in delivering timely and accurate medical diagnoses.

Industry Overview in the Target’s Specific Country

The clinical laboratory and medical diagnostics industry in Europe is experiencing significant growth driven by several factors, including an aging population, increasing prevalence of chron

View Source

Similar Deals

FUTRUE GmbH PharmaSGP Holding SE

2025

Public-to-Private (P2P) Pharmaceuticals (NEC) Germany
Varian Medical Systems, Inc. MeVis Medical Solutions AG

2015

Public-to-Private (P2P) Advanced Medical Equipment & Technology (NEC) Germany
GF BRYCK Ventures 2NA FISH GmbH

2026

Pre-Seed Stage Bio Diagnostics & Testing Germany
Novalis Biotech Altavo GmbH

2026

Series A Advanced Medical Equipment & Technology (NEC) Germany
磐霖资本 瑞博生物

2026

Public-to-Private (P2P) Proprietary & Advanced Pharmaceuticals China
Demant KIND

2026

Other Medical Equipment, Supplies & Distribution (NEC) Germany

Ephios Luxembourg S.a.r.l.

invested in

SYNLAB AG

in 2023

in a Public-to-Private (P2P) deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert